Vistagen Therapeutics, Inc. Common Stock (VTGN) is a publicly traded Healthcare sector company. As of May 21, 2026, VTGN trades at $0.64 with a market cap of $23.59M and a P/E ratio of -0.38. VTGN moved +1.22% today. Year to date, VTGN is -11.14%; over the trailing twelve months it is -75.67%. Its 52-week range spans $0.43 to $5.14. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces VTGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Helus Pharma Shares Plunge 33% Following 10.4-Point Phase 2 Anxiety Improvement: Helus Pharma shares plunged 33.2% to $6.41 after topline Phase 2 data for HLP004 in generalized anxiety disorder showed a 10.4-point improvement in 36 patients but fell short of investor expectations. At six months 67% responded and 39% remitted, while Vistagen’s PALISADE-3 Phase 3 trial failed its primary endpoint.
| Metric | Value |
|---|---|
| Price | $0.64 |
| Market Cap | $23.59M |
| P/E Ratio | -0.38 |
| EPS | $-1.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.14 |
| 52-Week Low | $0.43 |
| Volume | 822 |
| Avg Volume | 0 |
| Revenue (TTM) | $486.00K |
| Net Income | $-51.42M |
| Gross Margin | 0.00% |
1 analysts cover VTGN: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.